Anticoagulant Advancements for VTE in Children

We asked Professor Heleen van Ommen about a symposium presented on the ISTH 2022 congress in London, which was about pediatric thrombosis.

The Journey to Address Unmet Needs Across all Haemophilia Indications

Dr. Maria Elisa Mancuso chaired a symposium at the recent ISTH 2022 congress. The main topic was to try to understand which are the clinical met needs of haemophilia care.

Good practice statements for antithrombotic therapy in the management of COVID-19

Professor Alex Spyropoulos shared with us the guidance statement of the Scientific Standardization Committee of the ISTH about the good practice statements for antithrombotic therapy in the management of COVID-19. These statement was presented at the ISTH 2022 Congress in London. For more details, read the full article on the page of the Journal of Thrombosis and Haemostasis: https://onlinelibrary.wiley.com/doi/10.1111/jth.15809

Clinical Challenges in Patients with Venous Thromboembolism

Professor Walter Ageno shared us his thoughts on a symposium he took part on the recent ISTH 2022 congress, which addressed very practical issues in the management of patients with venous thromboembolism.

Navigating the Joint Health Journey for Patients With Hemophilia: How Can You Make A Lasting Impact?

Professor Margareth C. Ozelo shared us his thought about a symposium held at the recent ISTH 2022, which topic was about general issues related to joint health for hemophilia patient.

ISTH Proposal to Standardize Functional Assays in the Diagnosis of Heparin‐induced Thrombocytopenia

Professor Ishac Nazy held an interesting symposium durint the recent ISTH 2022 congress. He shared us his thought about ISTH proposal to standardize functional assays in the diagnosis of Heparin‐induced Thrombocytopenia.

Approaches to Standardisation and Monitoring for Haemophilia Gene Therapy: Consistency, Considerations and Challenges

Professor Johnny Mahlangu shared with us a symposium that they organized during the ISTH 2022 congress. They examined approaches to standardisation and monitoring for Haemophilia Gene Therapy.

Strategies for Assessing and Managing DOAC-Related Bleeding

Professor Deborah Siegal chaired an interesting symposium during the ISTH 2022 congress in London, the topic was strategies for assessing and managing DOAC-related bleeding.

Roles of FVIII in Endothelial Cell Biology: More than a Coagulation Factor?

We asked Professor Antonia Follenzi about their research data on the role of Factor VIII, what she presented on the recent ISTH 2022 congress in London.

Comparison between full dose and reduced dose enoxaparin in the management of cancer-associated venous thromboembolism

We asked Dr. Emma Leitinger about their work which was presented as a poster at the recent ISTH 2022 congress.

Brain cancers and the risk of intracranial hemorrhage with Direct Oral Anticoagulants versus Low Molecular Weight Heparin

We asked Professor Philip Haddad about anticoagulation treatment of patients with brain tumor. Professor Haddad presented a meta-analysis of the use of DOACs versus LMWH in this indication at the recent ISTH congress

The SAXOPHONE Study

We asked Professor Mark R. Payne about the new results of the SAXOPHONE Study what he presented at the recent ISTH 2022 congress. The study  investigated the use of apixaban in children with heart disease. (A Multi-Center, Multi-National Randomized Trial of Apixaban versus Standard of Care Anticoagulation for Thromboprophylaxis in Children with Congenital or Acquired Heart Disease)

ISTH Guidelines for Anticoagulation in COVID-19

We asked Professor Sam Schulman about the ISTH Guidelines on antithrombotic treatment in COVID-19.

“Ten months of needles, we’d better get it right!” - The Highlow Study

Professor Saskia Middeldorp presented the result of the Highlow Study at the recent ISTH 2022 congress in London, which investigated the different dosages of low molecular weight heparins in pregnant pregnant and postpartum women with a history of venous thromboembolism.

Current Guidelines on Perioperative Anticoagulation Management: DOACs

DOACs revolutionize the anticoagulation treatment in the last decade, but we have a few open question yet. We asked Professor James Douketis about the optimal perioperative management with regards to safety and efficacy.

Important messages from EULAR2021: Impact of air pollution on RA flares, effect of COVID-19 on RA care, osteoporosis care of men

Prof. Giovanni Adami speaks about the most important messages from EULAR 2021.

Medical Devices in Diabetes

Will SGLT2-inhibitors change the landscape?

Innate immunity in pancreatic islet inflammation

The artificial beta cell. When will the dream become reality?

Observational study of insulin pump treatment

The evidence for metformin is unclear?

The ORIGIN Study And Legacy Effects

EMPA-REG OUTCOME - a long-term, outcom study of empagliflozin in pateints with T2D at high CV risk

Principal investigator presenting the results of EMPA-REG OUTCOME trial

Mathematic modelling of fibrinolysis

Pre and perioperative factors modulate fibrinolysis in arthroplasty patients

Cellular and mechanical modulators of fibrin structure

Platelets, NETs and Immunity

Mechanisms by which DNA, histones and NETs stabilise clots

Free fatty acids modulate thrombin activity ov fibrinogen and destabilise fibrin clots

Genetics of thrombosis